Forma Therapeutics’ FT-7051 is Well-tolerated and Demonstrates Evidence of Activity in Initial Results from Ongoing Phase 1 Courage Study in Men with Metastatic Castration-resistant Prostate Cancer
Retrieved on:
Thursday, October 7, 2021
Biotechnology, General Health, Health, Pharmaceutical, Oncology, Prostate, Private Securities Litigation Reform Act, Man, Absorption, MCRPC, Grade, Ars, BRP Ramon Alcaraz (PS-16), Male, Prostate cancer, Conference, CBP, AR, BioMed Central, Protein, American Cancer Society, Veni, vidi, vici, John Worsfold, Sickle cell disease, Degenerative disease, LinkedIn, Safety, Cancer, HIV disease progression rates, SEC, Research, Pharmacology, Mortality, U.S. Securities and Exchange Commission, Radiation, PSA, Security (finance), AACR, Therapy, Survival, Forma, Patient, Disease, Nasdaq, Pharmaceutical industry, Medical imaging, Birth control, CBP/p300, Prostate Cancer, Forma Therapeutics, CBP/P300, PROSTATE CANCER, FORMA THERAPEUTICS
Preliminary results reported today include data as of Sept. 1, 2021, from eight men enrolled in the trial.
Key Points:
- Preliminary results reported today include data as of Sept. 1, 2021, from eight men enrolled in the trial.
- Three patients remain on study; five patients left the study (four due to disease progression and one withdrawal of consent).
- The 150 mg dose achieved drug concentrations that approached the predicted efficacious dose based on modeling with preclinical results.
- Skin biopsies of the men participating in the study demonstrated a reduction in H3K27AC, a marker of activity in the CBP/p300 pathway, the target of FT-7051.